Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study

Schuster, Herbert; Barter, Philip J.; Stender, Steen; Cheung, Rose; Bonnet, Jacques; Morrell, Jonathan; Watkins, Claire; Kallend, David; Raza, Ali

doi:10.1016/j.ahj.2003.10.004

Cited by 140 publications

(116 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As reported previously [13], this trial showed that rosuvastatin treatment enabled more patients to reach LDL-C goals and produced greater improvements in lipid profiles than did the other statins. Moreover, switching to equal or lower doses of rosuvastatin was a successful strategy for accomplishing these same changes.…”

Section: Introductionsupporting

confidence: 51%

“…Details of the trial design, patient eligibility requirements, and laboratory measurements have been reported previously [13]. Briefly, this randomized, open-label, 5-arm, parallel-group, multicenter trial (4522IL/0081) was Table 1 Baseline (S.D.)…”

Section: Methodsmentioning

confidence: 99%

“…The Measuring Effective Reductions in Cholesterol Using Rosuvastatin TherapY (MERCURY) I trial compared the effects of rosuvastatin vs. commonly used doses of atorvastatin, simvastatin, and pravastatin as well as the effects of switching to rosuvastatin from the other statins on lipid levels and achievement of LDL-C goals in 3140 hypercholesterolemic patients with CAD, atherosclerosis, or type 2 diabetes mellitus, or whose 10-year CAD risk is at least 20% [13]. As reported previously [13], this trial showed that rosuvastatin treatment enabled more patients to reach LDL-C goals and produced greater improvements in lipid profiles than did the other statins.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study

Cheung¹,

Morrell²,

Kallend³

et al. 2005

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 51%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study

Cheung¹,

Morrell²,

Kallend³

et al. 2005

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

“…Additionally, in various patient populations, rosuvastatin provided comparable or greater improvements in other atherogenic lipid measures and in achievement of lipid goals [19,26,27,28]. Moreover, switching to rosuvastatin from equivalent or higher doses of comparator statins has been shown to improve lipid goal achievement rates in high-risk patients compared with patients who did not switch [29, 30]. Continued assessment of rosuvastatin in large-scale pharmacoepidemiology studies strongly indicates that such benefits do not come at the expense of additional risk [31, 32].…”

Section: Discussionmentioning

confidence: 99%

Safety of Rosuvastatin: Update on 16,876 Rosuvastatin-Treated Patients in a Multinational Clinical Trial Program

Shepherd¹,

Vidt²,

Miller³

et al. 2007

Cardiology

View full text Add to dashboard Cite

Background: The safety and tolerability of rosuvastatin were assessed using data from 16,876patients who received rosuvastatin 5–40 mg in a multinational phase II/III/IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. Methods: An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005, was used to examine adverse events and laboratory data. Results: In placebo-controlled trials, adverse events irrespective of causality assessment occurred in 52.1% of patients receiving rosuvastatin 5–40 mg (n = 931) and 51.8% of patients receiving placebo (n = 483). In all controlled clinical trials with comparator statins, rosuvastatin 5–40 mg was associated with an adverse event profile similar to profiles for atorvastatin 10–80 mg, simvastatin 10–80 mg, and pravastatin 10–40 mg. Clinically significant elevations in alanine aminotransferase (>3 times the upper limit of normal [ULN] on at least 2 consecutive occasions) were uncommon (≤0.2%) in the rosuvastatin and comparator statin groups. Elevated creatine kinase >10 times ULN occurred in ≤0.3% of patients receiving rosuvastatin or other statins. Myopathy (creatine kinase >10 times ULN with muscle symptoms) possibly related to treatment occurred in 0.03% of patients taking rosuvastatin at doses ≤40 mg. The frequency of dipstick-positive proteinuria at rosuvastatin doses ≤20 mg was comparable to that seen with other statins, and the development of proteinuria was not predictive of acute or progressive renal disease. Both short- and long-term rosuvastatin treatment were associated with small increases in estimated glomerular filtration rate, with improvements appearing to be somewhat greater in those patients beginning treatment with greater renal impairment. In the phase II–IV program, no deaths were attributed to rosuvastatin; at doses of rosuvastatin ≤40 mg, 1 case of rhabdomyolysis occurred in a patient who received rosuvastatin 20 mg and concomitant gemfibrozil treatment. Conclusion: In summary, rosuvastatin was well tolerated by a broad range of patients with dyslipidemia, and its safety profile was similar to those of comparator statins investigated in the clinical program. (Nota bene: The clinical development program for rosuvastatin initially evaluated rosuvastatin doses up to 80 mg. Following completion of the phase III/IIIb program, a decision was made not to pursue marketing approval for the 80-mg dose because the additional lipid-modifying benefits of this dose did not justify the potential risks for use in the general population of patients with dyslipidemia.)

show abstract

“…The greater LDL cholesterol reductions with rosuvastatin were associated with a greater proportion of patients reaching NCEP-ATP III and European LDL cholesterol goals [55]. Another comparator trial, the MERCURY I study [56], confirmed the LDL cholesterol-lowering efficacy of rosuvastatin and its ability to enable more patients to reach goal [56]. Furthermore, this study demonstrated a significant improvement in goal achievement in patients who switched to rosuvastatin compared with those who remained on an equivalent dose of atorvastatin [56].…”

Section: Optimizing Ldl Cholesterol and Risk Reduction In Clinical Prmentioning

confidence: 63%

Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data

Olsson

2006

Curr Atheroscler Rep

View full text Add to dashboard Cite

In the 1960s, epidemiologic studies established a link between elevated serum cholesterol and increased risk of cardiovascular events. Extensive clinical trial data subsequently highlighted 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (ie, statins) as the most effective pharmacotherapy for lowering low-density lipoprotein (LDL) cholesterol, and showed that statin-mediated LDL cholesterol reductions were associated with significant improvements in cardiovascular outcomes. Such findings are reflected in current cardiovascular disease management guidelines, which focus on LDL cholesterol as the primary therapeutic target. These guidelines recommend target LDL cholesterol levels. However, a number of clinical trials have failed to identify an LDL cholesterol threshold level below which no further cardiovascular risk reduction occurs. Such findings suggest that optimal risk reduction may require greater reductions in LDL cholesterol than are currently being achieved. This review examines recent data highlighting the benefits of more pronounced LDL cholesterol reductions and considers how this could be achieved in clinical practice when many patients are not even reaching current targets.

show abstract

Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study

Cited by 140 publications

References 22 publications

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study

Safety of Rosuvastatin: Update on 16,876 Rosuvastatin-Treated Patients in a Multinational Clinical Trial Program

Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data

Contact Info

Product

Resources

About